Literature DB >> 19783098

Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery.

Kenichi Fukuda1, Masakazu Hayashida, Soichiro Ide, Naoko Saita, Yoshihiko Kokita, Shinya Kasai, Daisuke Nishizawa, Yasukazu Ogai, Junko Hasegawa, Makoto Nagashima, Megumi Tagami, Hiroshi Komatsu, Ichiro Sora, Hisashi Koga, Yuzuru Kaneko, Kazutaka Ikeda.   

Abstract

Individual differences in sensitivity to fentanyl, a widely used opioid analgesic, can hamper effective pain treatment. Still controversial is whether the single nucleotide polymorphisms (SNPs) of the human OPRM1 gene encoding the mu-opioid receptor influence the analgesic effects of opioids. We examined associations between fentanyl sensitivity and the two SNPs, A118G and IVS3+A8449G, in the human OPRM1 gene in 280 Japanese patients undergoing painful orofacial cosmetic surgery, including bone dissection. Regarding the A118G SNP in exon 1, in a cold pressor-induced pain test before surgery, less analgesic effects of fentanyl were shown in subjects carrying the minor G allele of the A118G SNP (median of difference between pain perception latencies before and after fentanyl injection [PPLpost-PPLpre]: 12s) compared with subjects not carrying this allele (PPLpost-PPLpre: 15s, p=0.046). Furthermore, the IVS3+A8449G SNP in intron 3, which represents a complete linkage disequilibrium block with more than 30 SNPs from intron 3 to the 3' untranslated region, was associated with 24-h postoperative fentanyl requirements. Subjects carrying the minor G allele of the IVS3+A8449G SNP required significantly less fentanyl for 24-h postoperative pain control (median: 1.5microg/kg) compared with subjects not carrying this allele (median: 2.5microg/kg, p=0.010). Although further validation is needed, the present findings shed light on the involvement of OPRM1 3' untranslated region polymorphisms in fentanyl sensitivity in addition to the A118G SNP and open new avenues for personalized pain treatment with fentanyl.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783098     DOI: 10.1016/j.pain.2009.09.004

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  33 in total

Review 1.  Pharmacogenetics of OPRM1.

Authors:  Richard C Crist; Wade H Berrettini
Journal:  Pharmacol Biochem Behav       Date:  2013-11-05       Impact factor: 3.533

Review 2.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

Review 3.  Genetics of perioperative pain management.

Authors:  Senthil Packiasabapathy; Nicole Horn; Senthilkumar Sadhasivam
Journal:  Curr Opin Anaesthesiol       Date:  2018-12       Impact factor: 2.706

4.  μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer.

Authors:  Andrey V Bortsov; Robert C Millikan; Inna Belfer; Richard L Boortz-Marx; Harendra Arora; Samuel A McLean
Journal:  Anesthesiology       Date:  2012-04       Impact factor: 7.892

5.  Pharmacological consequence of the A118G μ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca²⁺ channels in humanized mouse sensory neurons.

Authors:  Saifeldin Mahmoud; Annika Thorsell; Wolfgang H Sommer; Markus Heilig; Joan K Holgate; Selena E Bartlett; Victor Ruiz-Velasco
Journal:  Anesthesiology       Date:  2011-11       Impact factor: 7.892

6.  OPRM1, OPRK1, and COMT genetic polymorphisms associated with opioid effects on experimental pain: a randomized, double-blind, placebo-controlled study.

Authors:  Kwo Wei David Ho; Margaret R Wallace; Roland Staud; Roger B Fillingim
Journal:  Pharmacogenomics J       Date:  2019-12-06       Impact factor: 3.550

7.  Pharmacogenomic strain differences in cardiovascular sensitivity to propofol.

Authors:  Thomas A Stekiel; Stephen J Contney; Richard J Roman; Craig A Weber; Anna Stadnicka; Zeljko J Bosnjak; Andrew S Greene; Carol Moreno
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

Review 8.  Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges.

Authors:  Stephen Bruehl; A Vania Apkarian; Jane C Ballantyne; Ann Berger; David Borsook; Wen G Chen; John T Farrar; Jennifer A Haythornthwaite; Susan D Horn; Michael J Iadarola; Charles E Inturrisi; Lixing Lao; Sean Mackey; Jianren Mao; Andrea Sawczuk; George R Uhl; James Witter; Clifford J Woolf; Jon-Kar Zubieta; Yu Lin
Journal:  J Pain       Date:  2013-02       Impact factor: 5.820

9.  Do Resting Plasma β-Endorphin Levels Predict Responses to Opioid Analgesics?

Authors:  Stephen Bruehl; John W Burns; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; Daria Orlowska; Erik Schuster; Christopher R France
Journal:  Clin J Pain       Date:  2017-01       Impact factor: 3.442

Review 10.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.